VES001
Frontotemporal Degeneration (FTD-GRN)
Phase 2Active
Key Facts
About Vesper Bio
Vesper Bio is a Danish biotech advancing a novel therapeutic approach for neurodegenerative diseases by targeting the multifunctional receptor sortilin. The company's lead asset, VES001, is an oral small molecule designed to normalize progranulin levels in patients with FTD-GRN and is currently in Phase II trials. Building on foundational academic research, Vesper Bio is leveraging its platform to develop selective sortilin inhibitors with potential applications in Parkinson's disease and retinal neuropathies. As a private, clinical-stage company, it operates with a sense of urgency to address significant unmet medical needs in neurology.
View full company profile